[go: up one dir, main page]

UY26426A1 - Nuevos compuestos - Google Patents

Nuevos compuestos

Info

Publication number
UY26426A1
UY26426A1 UY26426A UY26426A UY26426A1 UY 26426 A1 UY26426 A1 UY 26426A1 UY 26426 A UY26426 A UY 26426A UY 26426 A UY26426 A UY 26426A UY 26426 A1 UY26426 A1 UY 26426A1
Authority
UY
Uruguay
Prior art keywords
new compounds
processes
preparation
treatment
compositions containing
Prior art date
Application number
UY26426A
Other languages
English (en)
Inventor
Laramie Mary Gaster
Thomas Daniel Heightman
Jean-Pierre Pilleux
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9926304.8A external-priority patent/GB9926304D0/en
Priority claimed from GB0017880A external-priority patent/GB0017880D0/en
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of UY26426A1 publication Critical patent/UY26426A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

La invención se refiere a nuevos derivados de isoquinolina y quinazolina que tienen actividad farmacológica, a los procedimientos para su preparación, a las composiciones que los contienen y a su uso en el tratamiento de diversos trastornos.
UY26426A 1999-11-05 2000-11-03 Nuevos compuestos UY26426A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9926304.8A GB9926304D0 (en) 1999-11-05 1999-11-05 Novel compounds
GB0017880A GB0017880D0 (en) 2000-07-20 2000-07-20 Novel compounds

Publications (1)

Publication Number Publication Date
UY26426A1 true UY26426A1 (es) 2001-05-31

Family

ID=26244692

Family Applications (1)

Application Number Title Priority Date Filing Date
UY26426A UY26426A1 (es) 1999-11-05 2000-11-03 Nuevos compuestos

Country Status (10)

Country Link
US (1) US20050239797A1 (es)
EP (1) EP1228043B1 (es)
JP (1) JP2003513075A (es)
AT (1) ATE286883T1 (es)
AU (1) AU1028601A (es)
DE (1) DE60017446T2 (es)
ES (1) ES2234683T3 (es)
PE (1) PE20010956A1 (es)
UY (1) UY26426A1 (es)
WO (1) WO2001032626A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1283199A4 (en) * 2000-05-16 2003-12-17 Takeda Chemical Industries Ltd MELANINE CONCENTRATING HORMONE ANTAGONISTS
DE10315569A1 (de) * 2003-04-05 2004-10-14 Merck Patent Gmbh Substituierte Pyrazolverbindungen
DE10315573A1 (de) 2003-04-05 2004-10-14 Merck Patent Gmbh Substituierte Pyrazole
DE10315571A1 (de) 2003-04-05 2004-10-14 Merck Patent Gmbh Pyrazolverbindungen
GB0316915D0 (en) * 2003-07-18 2003-08-20 Glaxo Group Ltd Compounds
EP1651612B9 (en) 2003-07-22 2012-09-05 Astex Therapeutics Limited 3,4-disubstituted 1h-pyrazole compounds and their use as cyclin dependent kinases (cdk) and glycogen synthase kinase-3 (gsk-3) modulators
ES2302174T3 (es) * 2004-01-16 2008-07-01 F. Hoffmann-La Roche Ag Derivados 1-bencil-5-piperacin-1-il-3,4-dihidro-1h-quinazolin-2-ona y derivados respectivos de 1h-benzo(1,2,6)tiadiacin-2,2-dioxido y 1,4-dihidro-benzo(d)(1,3)oxacin-2-ona como moduladores del receptor 5-hidroxitriptamina(5-ht) para tratamiento enfermed. sistema nervioso central.
US9066903B2 (en) * 2006-02-28 2015-06-30 The United States Of America As Represented By The Department Of Veterans Affairs Pharmacological treatment of Parkinson's disease
US20090099175A1 (en) * 2006-03-01 2009-04-16 Arrington Mark P Phosphodiesterase 10 inhibitors
EP2139481B1 (en) 2007-03-21 2013-08-21 The University Of Montana 1-[(2'-substituted)-piperazin-1'-yl]-isoquinolines as norepinephrine transporter inhibitor therapeutics and positron emission tomography imaging agents
EP2669270B1 (en) 2011-01-28 2018-01-03 Sato Pharmaceutical Co., Ltd. Indole-related compounds as urat1 inhibitors
US10092574B2 (en) 2012-09-26 2018-10-09 Valorisation-Recherche, Limited Partnership Inhibitors of polynucleotide repeat-associated RNA foci and uses thereof
KR101709127B1 (ko) * 2015-06-16 2017-02-22 경동제약 주식회사 Dpp-iv 억제제의 제조를 위한 신규 중간체, 이의 제조방법 및 이를 이용한 dpp-iv 억제제의 제조방법
CN112480007B (zh) * 2020-12-08 2022-11-18 宿迁市科莱博生物化学有限公司 一种1，3-二甲基-1h-吡唑-4-羧酸的合成方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3778440A (en) * 1970-12-07 1973-12-11 Sandoz Ag 1-substituted amino-isoquinolines and nitrates thereof
US3932412A (en) * 1970-12-07 1976-01-13 Sandoz, Inc. 1-(4-Hydroxyalkylpiperazino)-isoquinoline nitrates
IL112248A0 (en) * 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
BR9809092A (pt) * 1997-04-18 2002-01-22 Smithkline Beecham Plc Derivados de indol tendo atividade combinada de antagonista de receptor de 5ht1a, 5ht1b e 5ht1d
WO1998047868A1 (en) * 1997-04-18 1998-10-29 Smithkline Beecham Plc Heterocycle-containing urea derivatives as 5ht1a, 5ht1b and 5ht1d receptor antagonists
ATE404539T1 (de) * 1997-10-02 2008-08-15 Eisai R&D Man Co Ltd Kondensierte pyridinderivate
WO1999031086A1 (en) * 1997-12-12 1999-06-24 Smithkline Beecham Plc Quinolinepiperazine and quinolinepiperidine derivatives, their preparation and their use as combined 5-ht1a, 5-ht1b and 5-ht1d receptor antagonists
WO2000006575A2 (en) * 1998-07-28 2000-02-10 Smithkline Beecham Plc Azabicyclic compounds

Also Published As

Publication number Publication date
JP2003513075A (ja) 2003-04-08
EP1228043A1 (en) 2002-08-07
DE60017446T2 (de) 2006-03-02
ATE286883T1 (de) 2005-01-15
EP1228043B1 (en) 2005-01-12
WO2001032626A1 (en) 2001-05-10
AU1028601A (en) 2001-05-14
PE20010956A1 (es) 2001-09-15
US20050239797A1 (en) 2005-10-27
DE60017446D1 (de) 2005-02-17
ES2234683T3 (es) 2005-07-01

Similar Documents

Publication Publication Date Title
GB0111186D0 (en) Novel compounds
WO2000035919A3 (en) Quinoline derivatives
AU2002220715A1 (en) Indolsulfonyl compounds useful in the treatment of cns disorders
MY138836A (en) Quinoline derivatives and their use as 5-ht6 receptor ligands
TR200101859T2 (tr) Kemokin alıcı aktivitesinin modülatörleri olarak N-üreidoalkil-piperidinler
MXPA02012712A (es) N-ureidoheterocicloalquil-piperidinas como moduladores de la actividad del receptor de quimiocinas.
PT1274687E (pt) Derivados de 1,2,3,4-tetra-hidroisoquinolina
BR0309875A (pt) métodos e composições para tratamento de distúrbios do sistema nervoso periférico e novos compostos úteis para isto
TW200500344A (en) Novel compounds
MY133667A (en) Quinazoline ditosylate salt compounds
HK1054039A1 (en) Substituded beta-carbolines
UY26082A1 (es) Derivados de 1,4-diazabiciclo [3.2.2] nonan-4-carboxilato y -carboxamidas, su preparacion y su aplicacion en terapeutica
MY122771A (en) Heterocyclically substituted benzimidazoles, their preparation and use thereof
WO2002072536A8 (en) Urea derivatives having vanilloid receptor (vr1) antagonist activity
ATE302606T1 (de) N-ureidoalkylpiperidine als modulatoren der aktivität der chemokinrezeptoren
UY26426A1 (es) Nuevos compuestos
SE9802208D0 (sv) Novel compounds
SE9902765D0 (sv) Novel compounds
ATE433966T1 (de) Methylendipiperidinderivate
ATE439363T1 (de) Imidazo 2,1-b -1,3,4-thiadiazole sulfonamides
GB0320320D0 (en) Novel compounds
UY26085A1 (es) N-[-(4-aminofenil)-2,3-dihidro-1,4-benzodioxina-2-metanamina su preparacion y su aplicacion en terapeutica
SE9802209D0 (sv) Novel compounds
MX9604762A (es) Nuevas sulfonamidas y procedimiento para su preparacion.
BG105984A (bg) Използване на озанетант за приготвяне на лекарствени средства полезни за лечение на разстройства на настроението

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20120118